Business Wire

Postgraduate Institute for Medicine, in Partnership with RMEI Medical Education, Announces an Educational Awareness Campaign for World Arthritis Day

Jaa

Postgraduate Institute for Medicine (PIM) and RMEI Medical Education (RMEI) have launched the first in a three-part series of global medical education interventions to address ongoing gaps in clinical practice, and to raise awareness for World Arthritis Day by focusing on the importance of early diagnosis and access to evidence-based treatment in rheumatoid arthritis (RA). The partners hope the first activity will stimulate professional reflection on practice behavior and patient outcomes, while later content will address emerging data on therapeutic pathways and patient engagement.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171012005711/en/

The series is entitled Achieving Success in RA Assessment and Management: A Learner Pathway to Improve Patient Outcomes, and will incorporate alternating cycles of education, assessment, and recalibration of content to meet evolving healthcare provider needs.

“If pharmacological treatment for rheumatoid arthritis is started within 12 weeks after the onset of symptoms, this could minimize the level of joint impact over time and increase the chances of remission1,” noted Dr. Jeffrey Curtis, professor of medicine and director of the Arthritis Clinical Intervention Program at the University of Alabama at Birmingham, in the United States. “Both EULAR and ACR guidelines advocate for a treat-to-target approach with shared decision making. There has been a general failure to adopt this in clinical practice, and the weight of the evidence is that these approaches work to optimize care for patients with RA.”

Each of the 3 online courses will present learners with unique educational environments: the first, called Clinical Reflections™, uses a virtual clinical setting to allow learners to rethink decisions based on realistic patient care scenarios and to modify their management plans accordingly to affect behavioral change. The second, Clinical Convergence ®, engages learners by integrating video patient perspectives with clinical content to illustrate potential differences between clinician and patient perceptions of their care. The third and final course, Clinical Conversations™, teaches clinicians certain technical skills and a step-wise process for integrating shared decision-making into patient care, a core competency not taught extensively in medical school and not appropriately utilized by clinicians in various specialties and disciplines.

Supported by independent educational grant funding from Genzyme, a Sanofi Company, and Regeneron Pharmaceuticals, this advanced analytics-driven initiative is the first of its kind in the RA education field.

“Why this is important to patients with RA might seem obvious, since clinicians who engage in RA-related education tailored to specific drivers of educational need tend to improve the care they deliver to their patients,” said Jacqui Brooks, MBBCh, MRCPsych, Senior Vice President of Medical Strategy at RMEI. “Our research has shown that proactive monitoring of disease activity and selecting appropriate treatment options – particularly in patients with moderate to severe disease – as well as use of shared decision-making approaches, are areas of particular deficit. The Learner Pathway in RA will address these issues with laser-like focus.”

This initiative has been planned to support EULAR’s “Don’t Delay, Connect Today” campaign, an initiative for uniting the voices of People with Arthritis and Rheumatism (PARE) organizations, scientific member societies, and health professional associations, with the united goal of highlighting the importance of early diagnosis and access to treatment.

About RMEI Medical Education
Founded in 1990, RMEI Medical Education (RMEI) is one of the longest operating medical education companies in the US. With an emphasis on sophisticated learner analytics for program design, delivery, and assessment, RMEI works to elevate the dialogue on what makes for effective education. In designing innovative teaching modalities such as the Clinical Convergence™ platform for its 5 primary therapeutic areas, RMEI seeks to inspire greater collaboration within the care team and stronger commitment to patient engagement. For more information, visit www.rmei.com, call 856-672-3152, or e-mail at contact@rmei.com.

About EULAR
The European League Against Rheumatism (EULAR) is a pan-European, non-profit organization that represents people with arthritis/rheumatism, health professionals in rheumatology, and scientific societies of rheumatology across Europe. EULAR aims to reduce the burden of rheumatic and musculoskeletal diseases (RMDs) on the individual and society and to improve the treatment, prevention, and rehabilitation of them. It promotes the translation of research advances into improved daily care for people with RMDs, and fights for governing bodies in Europe to recognize the needs of people with RMDs.

EULAR’s members include scientific societies, health professional associations, patient organizations, corporate members and people with RMDs across Europe. 2017 marks the 70th anniversary of EULAR, marking 70 years of research and the collaboration between physicians, health professionals, and patients. For more information, please visit www.eular.org.

1 Van der Linden MP, le Cessie S, Raza K, et al. Long-Term Impact of Delay in Assessment of Patients with Early Arthritis. Arthritis Rheum. 2010;62(12):3537-3546.

Contact information

RMEI Medical Education
Dave Clausen, CHCP, 856-672-3152
contact@rmei.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Sunny Optics Officially Licenses ImmerVision Panomorph Lens Technology for Global Production13.12.2017 15:47Tiedote

ImmerVision, developer of exclusive and patented panomorph wide-angle imaging technology, is proud to announce that Sunny Optics (Zhongshan) Co., a subsidiary of Sunny Optical Technology (Group) Co. Ltd., a leading manufacturer of integrated optical components and products, has licensed panomorph lens technology for global production, and will deliver its first small form-factor panomorph high-resolution super-wide-angle lenses for smartphones and mobile devices in Q1 2018. Panomorph lens technology combines state-of-the-art optical design and advanced, optimized algorithms, including low-power dewarping, to produce high-resolution super-wide-angle images without distortion, even in low light conditions. Sunny Optical is the largest Chinese lens supplier for the most popular smartphone brands and OEM applications such as sports cameras, surveillance, 360 image capture, autom

Synacor Launches Enhancements to Zimbra Communications and Collaboration Suite13.12.2017 15:30Tiedote

Synacor Inc. (NASDAQ:SYNC) today announced the commercial launch of Zimbra 8.8. The easy-to-use collaboration platform comes with new user experience features such as Zimbra Drive for enterprise-level file sync and sharing and Zimbra Chat. The Network Edition features tech stack enhancements including real-time backup, ActiveSync across mobile and desktop, hierarchical storage management (HSM) that enables customers to move archival data to less expensive storage solutions, and improved delegated admin functionality. “Zimbra 8.8 is an exciting update for end users and technical decision makers,” said Marcus Teo, Vice President, Enterprise Sales & Marketing, Synacor. “Customers look to Zimbra for security, privacy and transparency through open code, extensibility, accessibility on multiple devices and deployment flexibility. This update builds on these tenets and incorporates enhancemen

GSMA Urges Members of the World Trade Organization to Prioritise and Accelerate Investment in Digital Future13.12.2017 15:00Tiedote

On the occasion of the 11th World Trade Organization (WTO) Ministerial Conference, GSMA Director General Mats Granryd called on government leaders to reform their regulatory frameworks in order to encourage a new wave of innovation and investment in digital infrastructure and services. Currently, 108 of the WTO's 164 members have made commitments to facilitate trade in telecoms services, such as the right to establish new telecoms companies, make foreign direct investment in existing companies and enable the cross-border transmission of telecoms services. “Today, more than 5.1 billion people – about two-thirds of the world’s population – subscribe to mobile services. With this broad reach, the mobile industry is a major driver in the global economy, expected to employ nearly 31 million people worldwide and contribute $4.2 trillion in economic value (4.9 per cent of GDP) in 2020,” said

DCS Telecom Selects LeoSat for Innovative Data Solution13.12.2017 13:03Tiedote

LeoSat Enterprises, which is launching a constellation of up to 108 low-earth-orbit communications satellites, has entered into an agreement with DCS Telecom, a leading telecoms provider of satellite and networking solutions in the Middle East, Africa and Asia. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171213005443/en/ DCS Telecom Selects LeoSat for Innovative Data Solution (Photo: Business Wire) DCS Telecom will use LeoSat to upgrade its existing satellite solutions, giving customers access to a unique low-latency network which is expected to revolutionize data connectivity. LeoSat’s system of low earth orbit communications satellites can achieve lower latency and stronger end-to-end security compared to traditional satellite and terrestrial solutions used today. This is achieved through an adv

Andersen Global Expands Presence in Germany with Addition of Thierhoff Müller & Partner13.12.2017 11:01Tiedote

Andersen Global is proud to announce an expanded presence in Germany as Thierhoff Müller & Partner, a tax and legal firm with offices in Leipzig and Frankfurt, combines its practice with Andersen Tax & Legal in Germany. Through its German member firms, Andersen Tax & Legal and Alegis Steuerberatungsgesellschaft mbH, Andersen Global now has more than 65 professionals focused on providing tax and legal services and business advice across five locations in Germany, including Cologne, Dusseldorf, and Merzig. “Thierhoff Müller is highly regarded in complex restructuring matters. Together with our existing legal and tax practice, we will be able to increase our service offerings for our clients,” said Stefan Kraus, Managing Partner of Andersen Tax & Legal in Germany. “We are dedicated to providing outstanding service and are adding additional competencies in tax and legal such as corporate r

Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs13.12.2017 11:00Tiedote

Aprecia Pharmaceuticals, LLC (“Aprecia”), The 3DP Pharmaceutical Company, and Cycle Pharmaceuticals, Ltd. (“Cycle”) today announced they have signed a partnership agreement to develop and commercialize orphan drugs using three-dimensionally printed (“3DP”) technology. The planned products will deliver quality-of-life improvements versus existing, approved orphan drugs, and will achieve this by utilizing Aprecia’s proprietary 3DP ZipDose® Technology platform. ZipDose® is the only three-dimensional printing technology used in a pharmaceutical drug product approved by the U.S. Food and Drug Administration. Antonio Benedetti, CEO of Cycle commented: “Many rare disease patients do not have a treatment option at all. For those rare diseases where there is an approved pharmaceutical treatment, patients continue to be burdened by sub-optimal drug formulations. Aprecia’s

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme